Vor Biopharma Inc. Segment Reporting Other Item Amount
Vor Biopharma Inc. (VOR) reported Segment Reporting Other Item Amount of $24.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-11
- Vor Biopharma Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $24.40M, a 98.13% decline year-over-year.
- Vor Biopharma Inc. segment reporting other item amount for the quarter ending 2025-06-30 was $1.31B.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month |
|---|---|---|
| 2026-06-30 | $24.40M 10-Q · filed 2026-08-11 | $218.06M 10-Q · filed 2026-08-11 |
| 2025-06-30 | $1.31B 10-Q · filed 2026-08-11 | $1.31B 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |